Clinical Trials Sponsored by LipimetiX Development, LLC

Total 1325 results

Janssen Research & Development, LLC

Completed

A Study of Seltorexant in Participants With Probable Alzheimer's Disease

Alzheimer Disease

United States
Janssen Research & Development, LLC

Completed

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Netherlands, Sweden, Denmark, France
Janssen Research & Development, LLC

Completed

A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

Sjogren's Syndrome

United States, Germany, Netherlands, Japan, Taiwan, Italy, France, Spain, Poland, Portugal
Janssen Research & Development, LLC

Completed

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

Depressive Disorder, Treatment-Resistant

United States
Janssen Research & Development, LLC

Completed

A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis (U-POPS)

Psoriasis | Arthritis, Juvenile | Juvenile Psoriatic Arthritis

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

Schizophrenia

Rwanda
Janssen Research & Development, LLC

Terminated

A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever

Dengue

Singapore
Janssen Research & Development, LLC

Terminated

A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV) (DAISY)

Respiratory Tract Infections

Belgium, Czechia, Taiwan, Japan, Hungary, Thailand, United States, Germany, Korea, Republic of, Turkey, China, Spain, Brazil, Bulgaria, Malaysia, Estonia, Argentina, Poland, Israel, Italy, Latvia, Mexico, Panama, Slovakia, Sweden, Ukraine
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Multiple Myeloma

Israel, Czechia, United States, Germany, Spain, Japan, United Kingdom, France, Brazil
Janssen Research & Development, LLC

Completed

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Depressive Disorder, Treatment-Resistant

United States, France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Bulgaria, Malaysia, South Africa, Turkey, Canada, Korea, Republic of, Brazil, Estonia, Hungary, Lithuania, Slovakia, Sweden, Czechia, A... and more
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of Bedaquiline (TMC207) in Participants With Multibacillary Leprosy

Leprosy, Multibacillary

Brazil
Janssen Research & Development, LLC

Active, not recruiting

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer (PALOMA-3)

Advanced or Metastatic Non-small Cell Lung Cancer

Italy, United States, Germany, Japan, China, Korea, Republic of, Israel, Portugal, Taiwan, Thailand, Malaysia, United Kingdom, Australia, Turkey, Poland, Spain, Brazil, Canada, Argentina, France
Janssen Research & Development, LLC

Temporarily not available

Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

Warm Autoimmune Hemolytic Anemia
Janssen Research & Development, LLC

Completed

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis (FRONTIER 1)

Plaque Psoriasis

United States, Korea, Republic of, Germany, France, Canada, Japan, Taiwan, Spain, United Kingdom, Poland
Janssen Research & Development, LLC

No longer available

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Belgium, Iceland, Portugal, Slovenia
Janssen Research & Development, LLC

Completed

A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

United States, United Kingdom, France, Sweden, Germany, Spain, Italy, Belgium, Israel, Netherlands
Janssen Research & Development, LLC

Completed

A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy

Interstitial Cystitis | Pigmentary Retinopathy | Pigmentary Maculopathy

United States
Janssen Research & Development, LLC

Completed

A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer

Metastatic Prostate Cancer

United States, Korea, Republic of, Australia, Poland, Taiwan, France, Thailand, Malaysia, Russian Federation, Canada, Bulgaria, Italy, Spain, Turkey, Sweden, Israel, Belarus, Ukraine, Brazil, Argentina, Belgium, Denmark, United Kingdom and more
Janssen Research & Development, LLC

Completed

A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma

Multiple Myeloma

China
SCRI Development Innovations, LLC

Terminated

A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

United States
Janssen Research & Development, LLC

Terminated

A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (LYRA)

Hidradenitis Suppurativa

United States, Germany, Canada, Japan, Netherlands, Spain, Australia, Poland
Janssen Research & Development, LLC

Completed

Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity

Insomnia

Germany, United States, Netherlands
Janssen Research & Development, LLC

Terminated

A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant

Depressive Disorder, Major

United States, United Kingdom
Janssen Research & Development, LLC

Completed

A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants

Healthy

Germany
Janssen Research & Development, LLC

Completed

A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Janssen Research & Development, LLC

Active, not recruiting

A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection (PROGRESS)

Crohn's Disease

United States, Poland
Janssen Research & Development, LLC

Completed

A Study of Paliperidone Palmitate 6-Month Formulation

Schizophrenia

United States, Korea, Republic of, Hong Kong, Taiwan, Malaysia, Czechia, Poland, Brazil, India, Spain, Argentina, Bulgaria, Turkey, Russian Federation, Ukraine, Hungary, South Africa, Mexico, Australia, France, Italy
Janssen Research & Development, LLC

Approved for marketing

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

Metastatic Castration-resistant Prostate Cancer

Brazil, Austria, Estonia, Israel, Mexico
Janssen Research & Development, LLC

Completed

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

Human Immunodeficiency Virus (HIV)

United States, Spain, South Africa
Janssen Research & Development, LLC

Completed

A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge

Healthy

Belgium
Janssen Research & Development, LLC

Approved for marketing

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Brazil, Germany, Italy, Netherlands, Romania, Switzerland, United Kingdom
Janssen Research & Development, LLC

Completed

A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795

Fatty Liver Disease

United States
Janssen Research & Development, LLC

Suspended

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

Crohn Disease | Ulcerative Colitis

Germany, United States, United Kingdom, Belgium
Janssen Research & Development, LLC

Completed

A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, Spain, Germany
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

Adenomatous Polyposis Coli

United States, Germany, France, Israel, Netherlands, Poland, Puerto Rico, Spain, Sweden
Janssen Research & Development, LLC

Terminated

Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

Germany
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Bulgaria, Ukraine, Russian Federation, Germany, Finland, Japan, France
Janssen Research & Development, LLC

Completed

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Spain, United States, Hungary, Georgia, Moldova, Republic of, Ukraine
Janssen Research & Development, LLC

Terminated

A Single and Multiple Ascending Dose Study of JNJ-64457744

Healthy | Hepatitis B, Chronic

New Zealand
Janssen Research & Development, LLC

Completed

A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis

Adenomatous Polyposis Coli

United States, Germany, Korea, Republic of, France, Netherlands, Spain, Puerto Rico
Janssen Research & Development, LLC

Completed

A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants

Healthy

United States
Janssen Research & Development, LLC

Terminated

A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Dermatitis, Atopic

United States, Argentina
Janssen Research & Development, LLC

Completed

A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis

Colitis, Ulcerative

United States, France, Belgium, Israel, Canada, Netherlands, Austria, Poland, Denmark, Germany
Janssen Research & Development, LLC

Completed

A Study in a Human Laboratory Model of Smoking Behavior

Smoking

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

Depressive Disorder, Major

Belgium, United Kingdom, Germany, United States, Netherlands

Clinical Trials Sponsored by LipimetiX Development, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations